Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.6 GBX | -1.89% | -8.77% | -55.93% |
May. 20 | London gets boost thanks to rate cut hopes | AN |
May. 20 | ValiRx shares jump as Cytolytix gets Knowledge Transfer Voucher grant | AN |
Business Summary
Number of employees: 16
Sales per Business
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Drug Development
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Suzanne Dilly
CEO | Chief Executive Officer | 46 | - |
Gerald Desler
DFI | Director of Finance/CFO | 79 | 06-08-31 |
Chief Tech/Sci/R&D Officer | - | 22-09-07 | |
Kumar Nawani
COO | Chief Operating Officer | - | - |
Mark Treharne
PRN | Corporate Officer/Principal | - | 20-09-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gerald Desler
DFI | Director of Finance/CFO | 79 | 06-08-31 |
Kevin Cox
CHM | Chairman | 65 | 20-06-25 |
Director/Board Member | 57 | Apr. 21 | |
Suzanne Dilly
CEO | Chief Executive Officer | 46 | - |
Director/Board Member | 46 | Apr. 21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 132,348,673 | 110,208,233 ( 83.27 %) | 0 | 83.27 % |
Company contact information
Sector
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-55.93% | 4.36M | |
+18.15% | 124B | |
+18.02% | 112B | |
-12.75% | 22.22B | |
+5.07% | 22.94B | |
-39.94% | 16.87B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- VAL Stock
- Company ValiRx plc